Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Erbez GeorgiaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,000Price:--
-
Feb 09, 2024 (filed on Feb 15, 2024)Insider Name:Wahlstrom MatsOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:99,988Price:--
-
Feb 09, 2024 (filed on Feb 15, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-99,988Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-44,991Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,997Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:44,991Price:$1.67
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,997Price:$1.67
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:Lanfear Dennis MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,218Price:$2.44
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:Reider PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,854Price:$2.44
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:McMichael Bryan JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,707Price:$2.44
Filings by filing date
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Erbez GeorgiaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,000Price:--
-
Feb 09, 2024 (filed on Feb 15, 2024)Insider Name:Wahlstrom MatsOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:99,988Price:--
-
Feb 09, 2024 (filed on Feb 15, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-99,988Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-44,991Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,997Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:44,991Price:$1.67
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Wahlstrom MatsOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,997Price:$1.67
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:Lanfear Dennis MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,218Price:$2.44
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:Reider PaulOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,854Price:$2.44
-
Jan 20, 2024 (filed on Jan 23, 2024)Insider Name:McMichael Bryan JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,707Price:$2.44
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | C/O DENNIS M. LANFEAR 201 REDWOOD SHORES PARKWAY, SUITE 200 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://www.coherus.com |
IR: | See website |
Key People | ||
Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer | Bryan Mcmichael Interim Chief Financial Officer | Theresa M. Lavallee Chief Development Officer | Paul Reider Chief Commercial Officer |
Business Overview |
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira. |
Financial Overview |
For the fiscal year ended 31 December 2023, Coherus Biosciences Inc revenues increased 22% to $257.2M. Net loss decreased 18% to $237.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 49% to $91.2M (expense), Loss on debt extinguishment decrease from $6.2M (expense) to $0K. |
Employees: | 306 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $629.46M as of Dec 31, 2023 |
Annual revenue (TTM): | $257.24M as of Dec 31, 2023 |
EBITDA (TTM): | -$189.41M as of Dec 31, 2023 |
Net annual income (TTM): | -$237.89M as of Dec 31, 2023 |
Free cash flow (TTM): | -$175.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $356.69M as of Dec 31, 2023 |
Shares outstanding: | 112,714,488 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |